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ABSTRACT  
INTRODUCTION: Speech difficulties are a common debilitating feature of 
Parkinson’s disease and we aimed to investigate whether speech difficulties are 
associated with striatal dopaminergic deficits and faster disease progression. 
METHODS: Using the Parkinson's Progression Markers Initiative database, 143 
early de novo Parkinson’s disease patients with speech difficulties were identified 
and matched 1:1 with 143 Parkinson’s disease patients without speech difficulties 
for age, disease duration, motor symptoms severity. We investigated differences in 
clinical features and striatal [123I]FP-CIT single photon emission computed 
tomography (SPECT) uptake in Parkinson’s disease patients with and without 
speech difficulties. Cox proportional hazards analysis was carried out to 
investigate whether speech difficulties were predictive of a faster motor 
progression and cognitive decline.   
RESULTS: Speech difficulties were more common in patients with akinetic-rigid 
motor compared to tremor-dominant phenotype. Parkinson’s disease patients with 
speech difficulties had lower resting tremor (P=0.027), higher autonomic 
dysfunction (P=0.034) and increased daytime sleepiness (ESS; P=0.048) 
compared to those without speech difficulties. Parkinson’s disease patients with 
speech difficulties had significant lower [123I]FP-CIT uptake in the striatum 
(P<0.001), caudate (P=0.003) and  putamen (P<0.001) compared to those without 
speech difficulties. The presence of speech difficulties was a predictor of cognitive 
decline [Hazard Ratio (HR): 0.341, 95% Confidence Interval (CI): 0.153–0.759; 
Wald: 6.945; P=0.008), whereas had no influence on motor progression (HR: 
0.885, 95% CI: 0.662–1.183; Wald: 0.680; P>0.10). 
CONCLUSION: Speech difficulties are associated with greater autonomic 
dysfunction, excessive daytime sleepiness and striatal dopaminergic deficit, and 
predictive of faster cognitive decline in early Parkinson’s disease. 
Keywords: Parkinson’s disease; Speech difficulties; Cognitive decline; SPECT. 
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INTRODUCTION  
Speech difficulties are very common and debilitating features of Parkinson’s 
disease (PD) occurring in up to 90% of the patients over the course of the disease, 
and significantly affecting their social interactions and quality of life1. Changes in 
voice and speech have been reported in early drug-naïve PD patients2, 3 and even 
as early as five years prior to PD diagnosis4. Speech difficulties in PD, collectively 
termed as hypokinetic dysarthria, are characterized by reduced voice amplitude, 
monotone, breathy, hoarse voice quality, and imprecise articulation5. It has been 
suggested that hypokinetic dysarthria is the result of bradykinesia and rigidity of 
the laryngeal muscles due to dopaminergic deficits6-8. However, previous studies 
investigating the effects dopamine replacement therapy on speech performance in 
PD yielded inconsistent results showing either no effects of dopamine replacement 
therapy on speech parameters8-11, or improvements in speech intelligibility, 
endurance and pitch variability following levodopa treatment in PD patients7, 12-15. 
Thus, the mechanisms underlying speech abnormalities in PD are still poorly 
understood and little is known on their prognostic value on PD progression. Here, 
we investigated whether speech difficulties are associated with presynaptic 
dopaminergic deficits using [123I]FP-CIT single photon emission computed 
tomography (SPECT) molecular imaging; and whether speech difficulties are 
linked to progression of symptoms in early de novo PD patients.  
 
METHODS 
Participants and clinical evaluation 
From the 412 PD patients included in the Parkinson’s Progression Markers 
Initiative (PPMI) database (www.ppmi-info.org/data), a total of 353 early de novo 
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PD patients had a complete three-year follow-up and were included in the analysis. 
All PD patients were recruited between 2010-2015, diagnosed with PD less than 
two years prior to a screening visit, never treated with dopamine replacement 
therapy and presented with two among bradykinesia, resting tremor and rigidity or 
with asymmetric resting tremor/bradykinesia at screening. The diagnosis was 
confirmed by the presence of dopaminergic deficit at [123I]FP-CIT SPECT 
imaging.  
 
The presence of speech difficulties was defined according to the Unified PD 
Rating Scale Part-III (UPDRS-III), Item 3.1 (Speech) ≥ 1. This item is a clinician-
based scale consisting of 5 scores, rating between 0 (normal) and 4 (most severe 
impairment). Using propensity scores, 143 PD patients with speech difficulties 
were matched 1:1 with 143 PD patients without speech difficulties for age, disease 
duration, UPDRS-III. All matching variables were balanced after propensity 
scores. 
 
Motor symptom severity was assessed with the UPDRS-III and staged with the 
Hoehn and Yahr (H&Y) scale. UPDRS-III score was calculated excluding Item 
3.1 (Speech). Each motor domain (bradykinesia, resting tremor, rigidity, postural 
instability) was calculated using specific UPDRS-III sub-items as follows: 
bradykinesia (Total score range 0–52) = sum of Item 3.4 finger tapping, item 3.5 
hand movements, item 3.6 pronation-supination movements of hands, item 3.7 toe 
tapping, item 3.8 leg agility, item 3.9 arising from chair, item 3.13 posture and 
item 3.14 body bradykinesia; rigidity (Total score range 0–20) = sum of Item 3.3 
rigidity (neck, upper limbs and lower limbs); resting tremor (total score range 0–
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24) = sum of item 3.17 rest tremor amplitude (lip/jaw, upper limbs and lower 
limbs) and item 3.18 constancy of tremor; axial (total score range 0–12) = sum of 
item 3.10 gait, item 3.11 freezing of gait and item 3.12 postural stability16. 
UPDRS-II score was calculated excluding Item 2.1 (Speech). 
 
PD motor phenotypes were identified as either tremor-dominant or akinetic-rigid 
using the numerical ratio, which was derived from a patient's mean tremor score 
and mean akinetic-rigidity score17. Patients with ratio < 0.8 were classified as 
akinetic-rigidity phenotype, patients with ratio > 1.0 were classified as tremor-
dominant phenotype and patients with ratio between 0.8 and 1 were classified as 
mixed subtype. Non-motor symptoms were assessed using UPDRS-I and the Scale 
for Outcomes for PD–Autonomic function (SCOPA-AUT). Neuropsychiatric 
symptoms were assessed with the short version of the 15-item Geriatric 
Depression Scale (GDS) and the State Trait Anxiety Total scale (STAI). Sleep 
disorders were assessed with the Epworth Sleeping Scale and REM sleep behavior 
disorder questionnaire (RBDQ). Cognitive impairment was measured using the 
Montreal cognitive assessment (MoCA). Olfactory dysfunction was measured by 
the University of Pennsylvania Smell Identification Test (UPSIT). Disability was 
estimated using the Modified Schwab & England Activity of Daily Living (ADL). 
 
This study is registered with ClinicalTrials.gov (No: NCT01141023). Each PPMI 
site has received approval from an ethical committee on human experimentation 
before the study’s initiation. Written informed consent for research was obtained 
from all individuals participating in the study. The present study was written 
according to the STROBE guidelines18. 
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Dopaminergic imaging 
SPECT images were obtained 4±0.5 h after administrating an injection of 
approximately 185 MBq [123I]FP-CIT. [123I]FP-CIT SPECT scans were analysed 
following the imaging technical operations manual (http://ppmi-info.org/). Raw 
SPECT data was acquired into a 128 x 128 matrix stepping each 3 degrees for a 
total of 120 (or 4 degrees for a total of 90) projections in a window centered on 
159±10%KeV. The total scan duration was 30-45 minutes. A Chang 0 attenuation 
correction was applied using a customised Mu determined empirically from the 
anthropomorphic brain phantom acquired at each site. A standard Gaussian 3D 
6.0mm filter was applied to each image volume and then normalised to standard 
Montreal Neurologic Institute space. Each scan was interpreted by two 
independent readers who were blinded to the subjects’ demographics and 
characteristics. For quantification, SPECT image volumes were spatially 
normalized to an Ioflupane template. The eight most prominent axial slices 
containing striatum were summed and then a standardized volume of interest 
(VOI) template was applied to this image. VOI analyses were performed on the 
left and right caudate and putamen with the occipital region serving as a reference 
tissue. Specific binding ratios (SBR) were calculated as the ratio of the caudate or 
putamen VOI count density divided by count density of the occipital cortex minus 
1. This measure approximates the binding potential, BPND, when the tracer is in 
equilibrium at the target site and was previously reported with Ioflupane SPECT19.  
 
Assessment of motor progression and cognitive decline 
Motor progression was defined as a change of one point in the H&Y scale at each 
follow-up visit. Cognitive decline was defined as MoCA score of ≤22 at the 
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follow-up visits. Follow-up visits took place in the outpatient unit of the reference 
hospitals once every 12 months. All early de novo PD patients were followed up 
for a three-year period. 
 
Statistical analysis 
Statistical analysis and graph illustration were performed with SPSS (version 20) 
and GraphPad Prism (version 6.0c) for MAC OS X, respectively. For all variables, 
variance homogeneity and Gaussianity were tested with Kolmogorov-Smirnov 
test.  
Group comparisons between PD patients with and without speech difficulties were 
carried out using the Student t-test (parametric variables) and Mann-Whitney U 
test (non-parametric variables) as appropriate. Categorical variables were 
compared using a χ2 test, P-values for each variable were calculated following 
Bonferroni’s multiple comparisons test. We interrogated correlations between the 
speech scores and imaging data using Spearman’s rank correlation and we applied 
Bonferroni’s multiple comparisons test. To investigate whether speech difficulties 
were predictive of a faster disease progression and development of cognitive 
impairment, two Cox proportional hazards analyses were carried out investigating 
the presence of speech difficulties as predictor of: (1) motor progression; (2) 
cognitive decline. The analyses have been repeated including age and gender as 
covariate. The time to occurrence of the first event in a category for a given 
subject was used in the Cox model. All data are presented as mean ± standard 
deviation (SD), and the level α was set for all comparisons at P<0.05, corrected. 
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RESULTS 
Clinical characteristics 
Speech difficulties were more common in de novo PD patients with akinetic-rigid 
motor compared to tremor-dominant phenotype (100/84; 69.9% vs 27/43; 18.9%, 
P<0.05).  
 
In order to avoid biases due to motor symptoms severity and disease duration, we 
performed a case-control analysis matching for age, disease duration and UPDRS-
III. With regards to UPDRS-III motor subscores, PD patients with speech 
difficulties had lower resting tremor (P=0.027) and global tremor (P=0.027) scores 
compared to those without speech difficulties. No difference was observed in 
bradykinesia, rigidity and postural instability subscores between the two groups 
(all P>0.10; Table 1).  
 
Early de novo PD patients with speech difficulties had higher autonomic 
dysfunction (P=0.034) and increased daytime sleepiness (ESS; P=0.048) 
compared to patients without speech difficulties. There were no differences in 
UPDRS-I, UPSIT and RBDQ scores, anxiety/depressive symptoms, cognitive 
function and ADL between de novo PD patients with and without speech 
difficulties (all P>0.10; Table 1).  
 
Imaging assessment: presynaptic dopaminergic function 
Early de novo PD patients with speech difficulties had lower [123I]FP-CIT uptakes 
in the striatum (P<0.001), caudate (P=0.003) and putamen (P=0.003) compared to 
those without speech difficulties (Table 2; Figure 1A and 1C). Worse speech 
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scores at the UPDRS-III item 3.1 were associated with lower [123I]FP-CIT uptakes 
in the striatum (rs=−0.24; P<0.001), caudate (rs=−0.21; P=0.006) and putamen 
(rs=−0.23; P<0.001; Figure 1B).  
 
Motor progression and cognitive decline 
Over a period of three years, 151 (42.8%) de novo PD patients showed motor 
progression and 27 (7.6%) of them developed cognitive impairment. Cox 
proportional hazards analysis showed that the presence of speech difficulties in 
early de novo PD patients predicts cognitive decline at a three-year follow-up 
[Hazard Ratio (HR): 0.341, 95% Confidence Interval (CI): 0.153–0.759; Wald: 
6.945; P=0.008; Figure 2], whereas has no influence on PD motor progression 
(HR: 0.885, 95% CI: 0.662–1.183; Wald: 0.680; P>0.10). These results were 
confirmed after the inclusion of age and gender as covariate. 
 
DISCUSSION 
Our findings indicate that early de novo PD patients with speech difficulties have 
greater autonomic dysfunction, excessive daytime sleepiness and striatal 
dopaminergic deficit compared to a cohort of PD patients without speech 
difficulties independently from disease duration, age and severity of overall motor 
symptoms. Moreover, the presence of speech difficulties in early de novo PD 
patients is linked to an increased risk of cognitive decline.  
 
We found a 42.8% prevalence of speech difficulties in our cohort of 353 early de 
novo PD patients, in line with previous studies showing that speech difficulties can 
occur in about 40% of early untreated PD patients3. Speech difficulties were more 
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common in akinetic-rigid PD patients. Increased bradykinesia and rigidity were 
the motor symptoms specifically associated with speech difficulties suggesting 
that speech impairment in PD may be linked to bradykinesia and rigidity of 
laryngeal muscles. A recent study investigating longitudinal changes of speech in 
55 early de novo PD patients has shown that worse speech performance according 
to quantitative acoustic vocal evaluation and UPDR-III (Speech) item 3.1 was 
associated with increased UPDRS-III motor scores and bradykinesia subscores20. 
At follow-up assessment, improvements in speech performance were closely 
related to dopamine replacement therapy and antiparkinsonian treatment-related 
improvements in motor symptoms and particularly in bradykinesia subscores20.  
 
Other studies have found a significant correlation between speech abnormalities 
and axial symptoms, in particular freezing of gait, in moderate PD patients who 
were on dopamine replacement therapy15, 21, 22. We did not find significant 
differences in axial subscores between early de novo PD patients with and without 
speech difficulties. This discrepancy may be explained by the different stages of 
the PD cohorts examined and the presence/absence of dopamine replacement 
therapy. 
 
We found that early de novo PD patients had significant lower striatal [123I]FP-CIT 
levels compared to those without speech difficulties and that lower striatal 
presynaptic dopaminergic function was associated with higher speech impairment. 
To our knowledge, this is the first study showing a link between striatal 
presynaptic dopaminergic deficits and speech impairment in PD. Previous positron 
emission tomography (PET)23-26 and functional magnetic resonance (fMRI) 
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studies27, 28 have investigated neuronal substrates of speech difficulties in PD. 
These neuroimaging studies have shown abnormal activation of the basal ganglia–
cerebellum–cortex circuit with altered recruitment of the orofacial motor cortex, 
supplementary motor cortex, cerebellum and an increased involvement of the 
premotor and prefrontal cortices in moderate PD patients on dopamine 
replacement therapy27, 28. A recent fMRI study, investigating speech related resting 
state functional connectivity in the ON and OFF medication states, showed an 
association between levodopa-induced changes in caudate-dorsolateral prefrontal 
cortex connectivity and speech improvement in PD patients suggesting a link 
between dopamine deficits and speech impairment in PD27. 
 
Among the non-motor symptoms, PD patients with speech difficulties showed 
worse dysautonomic dysfunction and excessive daytime sleepiness whereas 
anxiety, depressive symptoms and cognitive function did not differ between the 
two groups. Interestingly, we found that the presence of speech difficulties was 
associated with an increased risk of cognitive decline but did not predict motor 
progression over a three-year follow-up period. Two studies have investigated the 
role of PD-related speech difficulties in predicting cognitive dysfunction in 
smaller cohorts of PD patients29, 30 . Gago and colleagues29 found that speech 
impairment progression, as measured by the UPDRS-III (Speech) was the 
strongest predictor of dementia over a six-year period in 24 early stage PD patients 
without axial motor impairment at baseline. PD patients with speech difficulties 
showed more rapid declines at the Mini Mental Status Examination, Clock 
Drawing, Semantic Verbal Fluency and Block Design neuropsychological tests29. 
Subsequently, a more recent study using quantitative acoustic vocal assessment 
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showed that variation in the range of the fundamental voice frequency and in 
specific the speech index of rhythmicity can predict changes in cognitive status as 
measured by the Addenbrooke’s cognitive examination with 73.2% accuracy over 
a 2-year period30. Our study extends previous preliminary observations and 
provides robust evidence for the link and predictive role of speech impairment in 
the development of cognitive decline in a very large cohort of early stage patients 
with PD. 
 
A limitation of our study includes the absence of quantitative acoustic vocal 
assessment to assess speech difficulties in PD patients. However, the use of the 
clinician-based scale such as the UPDRS-III (Speech) item 3.1 may provide a 
simple tool for clinician to follow-up the progression of speech difficulties and 
monitor closely those PD patients who will be more likely to develop cognitive 
impairment. 
 
Our findings demonstrate that speech difficulties are associated with higher striatal 
dopaminergic deficits and worse symptomatology in early PD and are predictive 
of a faster cognitive decline. 
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FIGURE LEGEND 
Figure 1. Presynaptic dopaminergic deficit in the group of early de novo 
Parkinson’s disease patients with speech difficulties. (A) Box-plot showing 
decreased [123I]FP-CIT uptakes in the striatum, caudate and putamen of early de 
novo PD patients with speech difficulties. (B) Correlations between the degree of 
speech impairment (UPDRS-III, item 3.1) and [123I]FP-CIT uptake in the striatum 
(rs=−0.24; P<0.001), caudate (rs=−0.21; P=0.006) and putamen (rs=−0.23; 
P<0.001) of early de novo PD patients; ***P<0.001; **P<0.01. (C) [123I]FP-CIT 
SPECT images in Parkinson’s disease patients with and without speech 
difficulties. (Top) 55-year-old healthy control showing typical [123I]FP-CIT 
specific binding ratios in the caudate (SBR: 3.41) and putamen (SBR: 2.49) 
(Middle) 55-year-old male without speech difficulties exhibiting slight 
dopaminergic deficits as reflected by [123I]FP-CIT specific binding ratios in the 
caudate (SBR: 2.43) and putamen (SBR: 1.19); (Bottom) 55-year-old male with 
speech difficulties demonstrating larger striatal dopaminergic deficits as reflected 
by [123I]FP-CIT specific binding ratios in the caudate (SBR: 1.22) and putamen 
(SBR: 0.455). 
Figure 2. Overall survival curves for the development of cognitive 
impairment regarding to the presence of speech difficulties.  Patients with 
speech difficulties had an increased risk of developing cognitive impairment 
compared to those without speech difficulties (Log Rank (Mantel-Cox)=7.702; 
HR: 0.341, 95% CI: 0.153–0.759; Wald: 6.945; P=0.008). 
 
